Adma Biologics Stock Price, News & Analysis

ADMA Biologics reported a full year 2020 revenue of $42.2 million, marking a 44% increase from 2019. The company anticipates revenues of $250 million or more by 2024, driven by expanded plasma collection centers and improved product offerings. Despite revenue growth, ADMA faced a consolidated net loss of $75.7 million, an increase attributed to higher operational costs and investments in commercialization. The firm successfully expanded its plasma collection network and expects significant operational efficiencies with FDA approvals mid-year.

ADMA Biologics will report its financial results for Q4 and full year 2020 on March 25, 2021, after market close. The executive team will host a conference call at 4:30 p.m. ET to discuss these results, along with updates on the company's operations and products. ADMA produces FDA-approved plasma-derived biologics aimed at treating immunodeficient patients. The conference call can be accessed by dialing the provided numbers or via a live audio webcast on the company's investor website.

ADMA Biologics, Inc. (Nasdaq: ADMA) announced that CEO Adam Grossman will participate in a fireside chat at the Jefferies Virtual Plasma Summit on March 11, 2021, at 11:20 a.m. ET. Interested parties can view the event via a webcast on the company’s website, which will be archived for 90 days post-event. The company specializes in manufacturing and marketing FDA-approved plasma-derived biologics aimed at treating immunodeficient patients and preventing infectious diseases. ADMA's key products include BIVIGAM®, ASCENIV™, and NABI-HB®.

ADMA Biologics, Inc. (NASDAQ: ADMA) has received approval from the Korean Ministry of Food and Drug Safety for its Kennesaw, Georgia plasma collection center to sell source plasma in South Korea. This approval, alongside FDA approval for a Hepatitis B immunization program at the center, marks a significant regulatory milestone for ADMA. These advancements align with ADMA's strategy to enhance its global presence and secure its supply chain for plasma-derived biologics, aimed at treating immune deficiencies and infectious diseases.

ADMA Biologics highlights a poster presentation at the AAAAI 2021 Conference, showcasing a potential polyclonal hyperimmune globulin targeting S. pneumoniae. This therapy aims to improve clinical outcomes for immune-compromised patients, bridging the gap between vaccination and seroconversion. CEO Adam Grossman emphasized the importance of addressing infection risks despite existing vaccines. The company holds patents related to this hyperimmune globulin, aiming to expand its product pipeline for underserved patient populations.

ADMA Biologics, Inc. (Nasdaq: ADMA) announced that CEO Adam Grossman will participate in a fireside chat at the Raymond James Institutional Investor Conference on March 1, 2021, at 10:50 a.m. ET. The event will be available via webcast on the company’s website and will be archived for 90 days. ADMA focuses on manufacturing and developing specialty plasma-derived biologics, with three FDA-approved products aimed at treating immunodeficient patients and preventing infectious diseases.

ADMA Biologics, Inc. (NASDAQ: ADMA) has received FDA approval for its ADMA BioCenters plasma collection facility in Knoxville, Tennessee, which began operations in Q3 2020. This approval enhances the company's raw material supply chain and manufacturing control. ADMA aims to open up to ten plasma collection centers by 2024. The facility uses state-of-the-art equipment and employs 50 trained healthcare workers. This milestone is expected to improve product yields and margins, positioning ADMA for future growth and profitability.

ADMA Biologics, Inc. (Nasdaq: ADMA) announced that CMS has issued a permanent J-code (J1554) for ASCENIV™, effective April 1, 2021, enhancing reimbursement processes. This J-code is expected to facilitate patient access and simplify claims processing in outpatient settings. CEO Adam Grossman highlighted that this milestone supports the company's goal of achieving over $250 million in revenue by 2024. ASCENIV is a plasma-derived immune globulin approved for treating primary immunodeficiency in patients aged 12 and older.

ADMA Biologics reported preliminary unaudited revenues of $13.9 million for Q4 2020, marking a 16% increase from Q4 2019, and full-year revenues of $42.2 million, a 44% increase compared to 2019. The company anticipates significant value-creating FDA decisions in 2021 that could enhance supply chains and improve margins. ADMA plans to continue revenue growth and aims for revenues exceeding $250 million by 2024, supported by new plasma collection centers and expanded production capabilities.